A1M Pharma AB has changed its name to Guard Therapeutics International AB

Visit guardtherapeutics.com

We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

Our early clinical program consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.

Read more

CLINICAL STUDIES

ROSgard, our drug candidate, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

ROSgard™

Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more

INVESTOR RELATIONS

Video

See how ROSgard protects, cleans and repairs

ROSgard is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Press releases
  • 19 Sep 2019  ·  Regulatory information

    A1M Pharma announces positive top-line results from a phase 1a study of ROSgard

    Read more
Show more
Calendar & reports
News, reports & presentations
  • 23 Sep 2019 / Analysis

    A1M Pharma: A bright future ahead (Redeye)

    Read more
  • 13 Jun 2019 / Presentation

    Investor presentation, June 2019

    Read more
  • 21 May 2019 / Analysis

    Valuation of Monocl 2018

    Read more
  • 23 Aug 2018 / Analysis

    Valuation of AKI Monocl 2016

    Read more